PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Q3 FY25 Results
PACBQ3 FY25 ResultsAnnounced Nov 5, 2025, 07:00 AM| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 38.44 | 3.3% | 3.8% |
| Total Income | 38.44 | 3.3% | 3.8% |
| Expenditure | 77.32 | 8.6% | 25.7% |
| PBT | -37.62 | 10.2% | 38.0% |
| Net Profit | -38.00 | 9.4% | 37.4% |
| OPM | — | ||
| NPM | -98.85% | ||
| EPS | -0.13 | 7.1% | 40.9% |
PacBio Announces Q3 2025 Financial Results
04 May 2026 · 4 May, 8:03 am
Summary
PacBio announced its financial results for the quarter ended September 30, 2025. The company reported revenue of $38.4 million for Q3 2025. GAAP gross profit increased to $15.9 million, with a non-GAAP gross margin of 42%. GAAP net loss decreased to $38.0 million compared to the previous year. The company also introduced SPRQ-Nx chemistry, which is expected to significantly reduce sequencing costs.
Key Highlights
- 1
PacBio's revenue for Q3 2025 was $38.4 million.
- 2
Consumable revenue reached an all-time record at $21.3 million in Q3 2025.
- 3
GAAP gross profit for the third quarter of 2025 was $15.9 million, compared to $10.0 million for the third quarter of 2024.
- 4
Non-GAAP gross margin was 42% in the third quarter of 2025, compared to 33% for the third quarter of 2024.
- 5
GAAP net loss for the third quarter of 2025 was $38.0 million, compared to $60.7 million for the third quarter of 2024.
- 6
The company unveiled new SPRQ-Nx sequencing chemistry and consumables, expected to reduce sequencing costs by up to 40%.
Management Comments
Christian Henry
“While revenue came in slightly below our expectations this quarter, we achieved another all-time record for consumable revenue, expanded gross margins and continued to reduce our operating expenses. We also reached an important milestone on our technology roadmap with the introduction of SPRQ-Nx chemistry, which we believe will help dramatically lower the cost of human genome sequencing and make our technology economically competitive with many short read sequencing platforms. These achievements underscore our focus on disciplined growth and our commitment to making PacBio’s highly accurate long-read sequencing more accessible worldwide.”
Informational and educational content only. Not investment advice.